Objective: Dementia with Lewy bodies (DLB) is a common cause of dementia, but atrophy is mild compared to Alzheimer's disease. We propose that DLB is associated instead with severe synaptic loss, and we test this hypothesis in vivo using positron emission tomography (PET) imaging of C-UCB-J, a ligand for presynaptic vesicle protein 2A (SV2A), a vesicle membrane protein ubiquitously expressed in synapses.
Methods: We performed C-UCB-J PET in two DLB patients (an amyloid-negative male and an amyloid-positive female in their 70s) and 10 similarly aged healthy controls. The DLB subjects also underwent PET imaging of amyloid (C-PiB) and tau (F-AV-1451). C-UCB-J binding was quantified using non-displaceable binding potential (BP) determined from dynamic imaging. Changes in C-UCB-J binding were correlated with MRI regional brain volume, C-PiB uptake and F-AV-1451 binding.
Results: Compared to controls, both patients had decreased C-UCB-J binding, especially in parietal and occipital regions (FDR-corrected < 0.05). There were no significant correlations across regions between C-UCB-J binding and grey matter, tau (F-AV1451) or amyloid (C-PiB) in either patient.
Conclusions: Quantitative imaging of in vivo synaptic density in DLB is a promising approach to understanding the mechanisms of DLB, over and above changes in grey matter volume and concurrent amyloid/tau deposition.
Supplementary Information: The online version contains supplementary material available at 10.1186/s41824-020-00093-9.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7752786 | PMC |
http://dx.doi.org/10.1186/s41824-020-00093-9 | DOI Listing |
J Cereb Blood Flow Metab
December 2024
Molecular Imaging Center Antwerp (MICA), University of Antwerp, Wilrijk, Belgium.
Synaptic vesicle protein 2A (SV2A) is ubiquitously expressed in presynaptic terminals where it functions as a neurotransmission regulator protein. Synaptopathy has been reported during healthy ageing and in a variety of neurodegenerative diseases. Positron emission tomography (PET) imaging of SV2A can be used to evaluate synaptic density.
View Article and Find Full Text PDFPsychophysiology
January 2025
Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Vagus nerve stimulation (VNS) is the subject of exploration as an adjunct treatment for neurological disorders such as epilepsy, chronic migraine, pain, and depression. A non-invasive form of VNS is transcutaneous auricular VNS (taVNS). Combining animal models and positron emission tomography (PET) may lead to a better understanding of the elusive mechanisms of taVNS.
View Article and Find Full Text PDFbioRxiv
September 2024
Alzheimer's Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA.
Mol Psychiatry
October 2024
Center for Brain and Mind Health, Yale University, New Haven, CT, USA.
Eur J Nucl Med Mol Imaging
December 2024
Department of Radiology and Biomedical Imaging, Yale School of Medicine, 801 Howard Avenue, PO Box 208048, New Haven, CT, 06520- 8048, USA.
Purpose: [F]SynVesT-1, a positron emission tomography (PET) radiotracer for the synaptic vesicle glycoprotein 2A (SV2A), demonstrates kinetics similar to [C]UCB-J, with high brain uptake, fast kinetics fitting well with the one-tissue compartment (1TC) model, and excellent test-retest reproducibility. Challenges arise due to the similarity between k and [Formula: see text] (efflux rate of the reference region), when applying the simplified reference tissue model (SRTM) and related methods in [C]UCB-J studies to accurately estimate [Formula: see text]. This study evaluated the suitability of these methods to estimate [F]SynVesT-1 binding using centrum semiovale (CS) or cerebellum (CER) as reference regions.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!